The CYP3A5 non-expressing variant has been associated with reduced risk of neurotoxicity during treatment in 118 Spanish cancer patients (1/3 breast cancer) treated with paclitaxel [42], corresponding to an increased risk in expressors. The gene discussed is CYP3A5; the disease is cancer.